S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
OTCMKTS:ATRX

Adhera Therapeutics - ATRX Stock Forecast, Price & News

$0.55
0.00 (0.00%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.55
▼
$0.55
50-Day Range
$0.43
▼
$0.95
52-Week Range
$0.43
▼
$3.00
Volume
1 shs
Average Volume
2,908 shs
Market Capitalization
$1.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATRX stock logo

About Adhera Therapeutics (OTCMKTS:ATRX) Stock

Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRX Stock News Headlines

February 27, 2023 | finance.yahoo.com
Adhera Therapeutics, Inc. (ATRX)
January 25, 2023 | finance.yahoo.com
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
March 24, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
January 18, 2023 | seekingalpha.com
CGTX Cognition Therapeutics, Inc.
December 5, 2022 | seekingalpha.com
Adhera Therapeutics files for Nasdaq uplisting, $35M offering
October 9, 2022 | benzinga.com
Adhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, Predictions
September 21, 2022 | benzinga.com
Adhera Therapeutics Announces CEO, Senior...
September 19, 2022 | finance.yahoo.com
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
March 24, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
September 19, 2022 | seekingalpha.com
Adhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplist
July 19, 2022 | finance.yahoo.com
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
May 19, 2022 | seekingalpha.com
Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq
May 19, 2022 | finance.yahoo.com
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
January 20, 2022 | finance.yahoo.com
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
November 22, 2021 | finance.yahoo.com
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
November 8, 2021 | finance.yahoo.com
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
October 20, 2021 | finance.yahoo.com
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
October 15, 2021 | finance.yahoo.com
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
October 4, 2021 | finance.yahoo.com
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
September 13, 2021 | finance.yahoo.com
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
September 9, 2021 | finance.yahoo.com
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors
August 24, 2021 | finance.yahoo.com
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
August 2, 2021 | bizjournals.com
Melior Pharmaceuticals signs multimillion-dollar licensing deal for its experimental Parkinson's disease treatment
July 29, 2021 | baystreet.ca
Shares Spike On an Old Drug Being Used As a New Class of Drugs for Parkinson’s Disease
July 29, 2021 | finance.yahoo.com
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate
June 7, 2021 | baystreet.ca
Pharma Firm Shares Rips After Acquiring New Parkinson’s Drug
June 7, 2021 | ca.finance.yahoo.com
Melior Pharmaceuticals Announces Entry Into "Letter-of-Intent" for the Acquisition of Armesocarb by Adhera Therapeutics
See More Headlines
Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRX Company Calendar

Today
3/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATRX
CUSIP
N/A
CIK
737207
Web
adherathera.com
Phone
919-518-3748
Fax
206-830-9424
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,350,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-863.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.01
Quick Ratio
0.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($29.65) per share
Price / Book
-0.02

Miscellaneous

Outstanding Shares
3,180,000
Free Float
2,283,000
Market Cap
$1.75 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Dr. Zahed Subhan B.S. (Age 64)
    BS, L.L.B., LLB (Law), M.B.A., M.S., MBA, MS, CEO, Chief Scientific Officer & Chairman
    Comp: $8.33k
  • Mr. Andrew Albert Kucharchuk M.B.A. (Age 41)
    Vice Chairman, COO, Acting CFO & Chief Bus. Officer
    Comp: $186k

Key Competitors

View All Competitors













ATRX Stock - Frequently Asked Questions

How have ATRX shares performed in 2023?

Adhera Therapeutics' stock was trading at $0.82 on January 1st, 2023. Since then, ATRX stock has decreased by 32.9% and is now trading at $0.55.
View the best growth stocks for 2023 here.

When did Adhera Therapeutics' stock split?

Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

What is Adhera Therapeutics' stock symbol?

Adhera Therapeutics trades on the OTCMKTS under the ticker symbol "ATRX."

How do I buy shares of Adhera Therapeutics?

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adhera Therapeutics' stock price today?

One share of ATRX stock can currently be purchased for approximately $0.55.

How much money does Adhera Therapeutics make?

Adhera Therapeutics (OTCMKTS:ATRX) has a market capitalization of $1.75 million. The company earns $-6,350,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How can I contact Adhera Therapeutics?

Adhera Therapeutics' mailing address is P.O. BOX 2161, WAKE FOREST NC, 27588. The official website for the company is adherathera.com. The company can be reached via phone at 919-518-3748, via email at info@adherathera.com, or via fax at 206-830-9424.

This page (OTCMKTS:ATRX) was last updated on 3/24/2023 by MarketBeat.com Staff